Cefoxitin

CHEMBL996 Phase 4 Onaylandı Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

427.5 g/mol

LogP

—

Phase

4

A cephamycin antibiotic with strong anaerobic coverage, commonly used for intra-abdominal, pelvic, and mixed aerobic-anaerobic infections as well as surgical prophylaxis. It is highly resistant to beta-lactamases produced by anaerobic bacteria. Its coverage profile makes it particularly suited to procedures involving the bowel or female pelvic organs.

Moleküler Ağırlık

427,5000 g/mol

LogP

0,00

TPSA

202,00 Å²

Lipinski RO5

Geçer

Terapötik Alanlar

Infectious Disease Pancreatic Cancer Colorectal Cancer

Etki Mekanizması

Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), preventing transpeptidation and cross-linking of peptidoglycan chains. This weakens the bacterial cell wall, leading to osmotic lysis and cell death.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanizma

Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), preventing transpeptidation and cross-linking of peptidoglycan chains. This weakens the bacterial cell wall, leading to osmotic lysis and cell …

2D Yapı

SVG PNG

Cite this structure

Embed this structure

SMILES

CO[C@@]1(NC(=O)Cc2cccs2)C(=O)N2C(C(=O)O)=C(COC(N)=O)CS[C@@H]21

InChI

InChI=1S/C16H17N3O7S2/c1-25-16(18-10(20)5-9-3-2-4-27-9)13(23)19-11(12(21)22)8(6-26-15(17)24)7-28-14(16)19/h2-4,14H,5-7H2,1H3,(H2,17,24)(H,18,20)(H,21,22)/t14-,16+/m1/s1

Molecular Formula

C16H17N3O7S2

HBD / HBA

3 / 9

Döndürülebilir Bağlar

8

Ağır Atomlar

28

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

A cephamycin antibiotic with strong anaerobic coverage, commonly used for intra-abdominal, pelvic, and mixed aerobic-anaerobic infections as well as surgical prophylaxis. It is highly resistant to beta-lactamases produced by anaerobic bacteria. Its coverage profile makes it particularly suited to procedures involving the bowel or female pelvic organs.

Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), preventing transpeptidation and cross-linking of peptidoglycan chains. This weakens the bacterial cell wall, leading to osmotic lysis and cell death.

Yes, Cefoxitin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL996. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 441199. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Hasta dostu bilgi mi arıyorsunuz?

Cefoxitin PillFYI'da

Yapı

Hızlı Veriler

Formül: C16H17N3O7S2
Eş Anlamlılar: 1

Dış Bağlantılar

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.